RKI-1447 dihydrochloride NEW
| Price | $39 |
| Package | 2mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-28 |
Product Details
| Product Name: RKI-1447 dihydrochloride | CAS No.: 1782109-09-4 |
| Supply Ability: 10g | Release date: 2025/04/28 |
Product Introduction
Bioactivity
| Name | RKI-1447 dihydrochloride |
| Description | RKI 1447 dihydrochloride is an effective and selective ROCK inhibitor (ROCK1 IC50=14.5 nM, ROCK2 IC50=6.2 nM). RKI 1447 dihydrochloride can inhibit the growth of colorectal cancer cells and promote cell apoptosis. |
| In vitro | RKI 1447 effectively inhibits the phosphorylation of ROCK substrates MLC-2 and MYPT-1 in human cancer cells, specifically demonstrating no impact on AKT, MEK, and S6 kinase phosphorylation even at high concentrations up to 10 μM. Its potency ranges from 0.003-10 μM in targeting these substrates, highlighting its strong anticancer activity, particularly against colorectal carcinoma (CRC). Notably, at 10-320 μM for 24 hours, RKI 1447 significantly reduces the growth of CRC cell lines HCT-8 and HCT-116, and at 20-80 μM over the same period, it triggers apoptosis in a dose-dependent manner. Experimental results, including decreased cell viability and increased apoptosis in these cell lines, underscore RKI 1447's effective dose-dependent response, with Western Blot analysis also confirming the reduction of P-MLC-2 levels at concentrations starting from 100 nM, without affecting total MLC-2 levels. |
| In vivo | RKI 1447, administered at 200 mg/kg intraperitoneally (i.p.) daily for 14 days, effectively inhibits mammary tumor growth in MMTV/neu transgenic mice, demonstrating an 87% reduction in tumor volume growth compared to the control group. This compound, when given at a dose of 100 mg/kg i.p. once every three days for the same duration, also demonstrates significant antitumor activity against colorectal cancer (CRC) in 5-week-old male BALB/C nude mice, efficiently blocking tumor growth. Importantly, RKI 1447 does not exhibit physiological toxicity in mice, indicating its potential safety and efficacy for in vivo cancer treatment applications. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/25Kg/Bag |
VIP5Y
|
Hebei Mujin Biotechnology Co.,Ltd
|
2021-05-10 | |
| $1.00/1kg |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2024-03-26 | |
| $0.00/1kg |
VIP1Y
|
Hebei Junhua Import and Export Co., LTD
|
2025-03-25 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY